发布求助
文献互助 智能选刊 最新文献

European Cardiology Review最新文献

筛选
英文 中文
Valvular Heart Disease in Patients with Chronic Kidney Disease. 慢性肾病患者的瓣膜性心脏病
IF 3
European Cardiology Review Pub Date : 2022-01-31 eCollection Date: 2022-02-01 DOI: 10.15420/ecr.2021.25
Konstantina Kipourou, Jamie M O'Driscoll, Rajan Sharma
{"title":"Valvular Heart Disease in Patients with Chronic Kidney Disease.","authors":"Konstantina Kipourou,&nbsp;Jamie M O'Driscoll,&nbsp;Rajan Sharma","doi":"10.15420/ecr.2021.25","DOIUrl":"https://doi.org/10.15420/ecr.2021.25","url":null,"abstract":"<p><p>Valvular heart disease (VHD) is highly prevalent in patients with chronic kidney disease (CKD) from the early stages to end-stage renal disease (ESRD). Aortic and mitral valves are the most frequently affected, leading to aortic valve and/or mitral annular calcification, which, in turn, causes either valve stenosis or regurgitation at an accelerated rate compared with the general population. Tricuspid regurgitation is also prevalent in CKD and ESRD, and haemodialysis patients are at an increasingly high risk of infective endocarditis. As for pathophysiology, several mechanisms causing VHD in CKD have been proposed, highlighting the complexity of the process. Echocardiography constitutes the gold standard for the assessment of VHD in CKD/ESRD patients, despite the progress of other imaging modalities. With regard to treatment, the existing 2017 European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines on the management of VHD addressing patients with normal kidney function are also applied to patients with CKD/ESRD.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/71/ecr-17-e02.PMC8819604.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39914407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics. 2021年欧洲心力衰竭指南:个体化治疗的案例
IF 3
European Cardiology Review Pub Date : 2022-01-28 eCollection Date: 2022-02-01 DOI: 10.15420/ecr.2021.57
Nesan Shanmugam
{"title":"The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics.","authors":"Nesan Shanmugam","doi":"10.15420/ecr.2021.57","DOIUrl":"https://doi.org/10.15420/ecr.2021.57","url":null,"abstract":"© RADCLIFFE CARDIOLOGY 2022 www.ECRjournal.com The field of heart failure (HF) has seen the development of unparalleled evidence-based therapies over the last 30 years, with continuous improvement in survival and quality of life for our patients. It is unquestionably an exciting time to be considering or pursuing HF as a subspecialty. Pivotal to and underpinning these advances is the guidance provided by international HF guidelines, particularly from the European Society of Cardiology (ESC). The new 2021 ESC HF guidelines have a total of 41 new and 15 modified recommendations from the 2016 document.1","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/cb/ecr-17-e01.PMC8819603.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39914406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Presentation Award Winner: Polysaccharide Peptide of Ganoderma lucidum Reduces Endothelial Injury in Stable Angina and High-risk Patients. 口服报告奖得主:灵芝多糖肽减少稳定型心绞痛和高危患者的内皮损伤。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO3
Eliana Susilowati, Djanggan Sargowo, Nadia Ovianti
{"title":"Oral Presentation Award Winner: Polysaccharide Peptide of <i>Ganoderma lucidum</i> Reduces Endothelial Injury in Stable Angina and High-risk Patients.","authors":"Eliana Susilowati,&nbsp;Djanggan Sargowo,&nbsp;Nadia Ovianti","doi":"10.15420/ecr.2021.16.PO3","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO3","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/77/ecr-16-e59.PMC8785058.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Oral Presentation Award Winner: Clinical Efficacy of Intracoronary Papaverine After Nicorandil Administration for Safe and Optimal Fractional Flow Reserve Measurement. 口腔报告奖得主:尼可地尔给药后冠状动脉内罂粟碱用于安全、最佳的血流储备分数测量的临床疗效。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO4
Shinjo Sonoda
{"title":"Oral Presentation Award Winner: Clinical Efficacy of Intracoronary Papaverine After Nicorandil Administration for Safe and Optimal Fractional Flow Reserve Measurement.","authors":"Shinjo Sonoda","doi":"10.15420/ecr.2021.16.PO4","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO4","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/94/ecr-16-e60.PMC8785100.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes. 异柠檬酸脱氢酶在心肌细胞直接重编程中的作用。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO8
Tomoaki Ishida, Tomoe Ueyama, Ai Baba, Koji Hasegawa, Teruhisa Kawamura
{"title":"The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes.","authors":"Tomoaki Ishida,&nbsp;Tomoe Ueyama,&nbsp;Ai Baba,&nbsp;Koji Hasegawa,&nbsp;Teruhisa Kawamura","doi":"10.15420/ecr.2021.16.PO8","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO8","url":null,"abstract":"© RADCLIFFE CARDIOLOGY 2021 Access at: www.ECRjournal.com Objectives: Direct reprogramming with introduction of Gata4, Mef2c and Tbx5 (GMT) genes involved in cardiogenesis can convert fibroblasts to induced cardiomyocyte-like cells (iCMs), whereas only a low percentage of iCMs are obtained due to the low proliferative capacity. Recent studies suggest that oestrogen-related receptors (ERRs) are involved in cardiomyocyte maturation during the differentiation from pluripotent stem cells. In addition, ERRγ regulates the density and morphology of mitochondria in matured cardiomyocytes accounting for prominent aerobic metabolism. ERRγ is also known to induce the transcription of isocitrate dehydrogenases (IDHs), one of the tricarboxylic acid cycle regulators. In the present study, we investigate whether ERRγ-IDHmediated mitochondria regulation is involved in cellular metabolism during direct reprogramming to iCMs.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cd/99/ecr-16-e64.PMC8785091.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Retrospective Study to Assess the Effect of Telmisartan on Urine Albumin to Creatinine Ratio in Indian Hypertensive Patients. 替米沙坦对印度高血压患者尿白蛋白/肌酐比值影响的回顾性研究。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO7
Balram Sharma, Hanmant Barkate, Sachin Suryawanshi, Mayur Jadhav, Obaidullah Khan, Gauri Dhanaki
{"title":"Retrospective Study to Assess the Effect of Telmisartan on Urine Albumin to Creatinine Ratio in Indian Hypertensive Patients.","authors":"Balram Sharma,&nbsp;Hanmant Barkate,&nbsp;Sachin Suryawanshi,&nbsp;Mayur Jadhav,&nbsp;Obaidullah Khan,&nbsp;Gauri Dhanaki","doi":"10.15420/ecr.2021.16.PO7","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO7","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/01/ecr-16-e63.PMC8785104.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Polyunsaturated Fatty Acids EPA and DHA Prevent Myocardial Infarction-induced Heart Failure by Inhibiting p300-HAT Activity in Rats. 多不饱和脂肪酸EPA和DHA通过抑制p300-HAT活性预防大鼠心肌梗死性心力衰竭。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO12
Yoichi Sunagawa, Ayumi Katayama, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Koji Hasegawa, Tatsuya Morimoto
{"title":"The Polyunsaturated Fatty Acids EPA and DHA Prevent Myocardial Infarction-induced Heart Failure by Inhibiting p300-HAT Activity in Rats.","authors":"Yoichi Sunagawa,&nbsp;Ayumi Katayama,&nbsp;Masafumi Funamoto,&nbsp;Kana Shimizu,&nbsp;Satoshi Shimizu,&nbsp;Yasufumi Katanasaka,&nbsp;Yusuke Miyazaki,&nbsp;Koji Hasegawa,&nbsp;Tatsuya Morimoto","doi":"10.15420/ecr.2021.16.PO12","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO12","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/e3/ecr-16-e68.PMC8785061.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Chrysanthemum morifolium Extract Prevents the Development of Doxorubicin-induced Heart Failure. 菊花提取物可预防阿霉素引起的心力衰竭。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO9
Masaya Ono, Yoichi Sunagawa, Yasufumi Katanasaka, Koji Hasegawa, Tatsuya Morimoto
{"title":"<i>Chrysanthemum morifolium</i> Extract Prevents the Development of Doxorubicin-induced Heart Failure.","authors":"Masaya Ono,&nbsp;Yoichi Sunagawa,&nbsp;Yasufumi Katanasaka,&nbsp;Koji Hasegawa,&nbsp;Tatsuya Morimoto","doi":"10.15420/ecr.2021.16.PO9","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO9","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/d0/ecr-16-e65.PMC8785085.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Natural Product Zerumbone Suppresses Pressure Overload-Induced Cardiac Dysfunction by Inhibiting Cardiac Hypertrophy and Fibrosis. 天然产物Zerumbone通过抑制心脏肥大和纤维化来抑制压力超负荷引起的心功能障碍。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO14
Mikuto Tojima, Yasufumi Katanasaka, Yoichi Sunagawa, Koji Hasegawa, Tatsuya Morimoto
{"title":"The Natural Product Zerumbone Suppresses Pressure Overload-Induced Cardiac Dysfunction by Inhibiting Cardiac Hypertrophy and Fibrosis.","authors":"Mikuto Tojima,&nbsp;Yasufumi Katanasaka,&nbsp;Yoichi Sunagawa,&nbsp;Koji Hasegawa,&nbsp;Tatsuya Morimoto","doi":"10.15420/ecr.2021.16.PO14","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO14","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/25/ecr-16-e70.PMC8785086.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Presentation Award Winner: β3 Adrenergic Receptors in the Sinoatrial Node for Heart Rate Regulation. 口头报告奖得主:窦房结中β3肾上腺素能受体对心率调节的作用。
IF 3
European Cardiology Review Pub Date : 2021-12-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.16.PO2
Shu Nakao, Kazuki Yanagisawa, Tomoe Ueyama, Koji Hasegawa, Teruhisa Kawamura
{"title":"Oral Presentation Award Winner: β3 Adrenergic Receptors in the Sinoatrial Node for Heart Rate Regulation.","authors":"Shu Nakao,&nbsp;Kazuki Yanagisawa,&nbsp;Tomoe Ueyama,&nbsp;Koji Hasegawa,&nbsp;Teruhisa Kawamura","doi":"10.15420/ecr.2021.16.PO2","DOIUrl":"https://doi.org/10.15420/ecr.2021.16.PO2","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2021-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/42/ecr-16-e58.PMC8785093.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39879120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信